Systemic treatment with resveratrol reduces the progression of experimental periodontitis and arthritis in rats

Mônica G. Corrêa1, *, Paula Rodrigues Pires1, Fernanda Vieira Ribeiro1, Suzana Peres Pimentel1, Fabiano Ribeiro Cirano1, Marcelo Henrique Napimoga2, Marcio Z. Casati1, Renato Corrêa Viana Casarin1*

1 Dental Research Division, School of Dentistry, Paulista University, São Paulo, São Paulo, Brazil, 2 Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, SP, Brazil

* monica.grazieli@hotmail.com (MGC); casarinrcv@yahoo.com.br (RCVC)

Abstract

Rheumatoid arthritis and periodontitis are chronic inflammatory diseases which has been closely associated due to the nature of immune-inflammatory imbalance response. Resveratrol is a natural product with biological properties that may promote immunomodulatory effects on host response. This study investigated resveratrol continuous administration effect on experimental periodontitis and arthritis progression in rats. Thirty-five rats were assigned to the following groups: 1—experimental arthritis + experimental periodontitis + placebo (RA+EP+PL) (n = 12); 2 –RA+EP+ ibuprofen (RA+PE+IB) (n = 11); 3—RA+EP+ resveratrol (RA+PE+RSV) (n = 11). After euthanasia, the specimens were processed for morphometric analysis of bone loss, and the gingival tissue surrounding the first molar was collected for quantification of inflammatory markers using a Luminex/MAGpix assay and anti-citrullinated protein antibody (ACCPA) levels were measured by ELISA assay. Serum level of rheumatoid factor (RF) was measured by ELISA assay. Paw edema was analyzed using a plethysmometer. Higher bone loss was observed in PL group, when compared to IB and RSV groups. RSV group presented higher IL-4 concentration than PL and IB groups. Resveratrol reduced RF serum levels and both IB and RSV decreased ACCPA gingival levels. Besides, paw swelling level was significantly lower in IB and RSV groups in the 21th day and only in RSV group in the 28th day. Histological analyzes showed smooth articular surface and higher width of the subchondral cortical in RSV group. Resveratrol showed modulatory effect and seems to reduce the inflammatory signs of arthritis and articular damage throughout the time.

Introduction

Rheumatoid arthritis is a chronic inflammatory autoimmune disease with a prevalence of 0.5% to 1.0% in adults in industrialized countries that results in bone and cartilage loss [1]. On the other hand, severe periodontitis has a prevalence of 10% a 15% [2] which can result in tooth...
loss. Both conditions are host-mediated by production of exacerbated immune-inflammatory mediators, which lead to tissue destruction and to the maintenance of the inflammatory profile [3, 4]. Periodontal disease is a bacterial and chronic inflammatory condition that leads to the occurrence of supporting tissue destruction [3]. Moreover, different studies have associated the oral bacterial infection (bacterial load or serum titre measurement) and RA trigger and progression [5].

Relevant clinical studies, with considerable number of included subjects, have shown worst periodontal condition, higher risk of edentulism, higher prevalence of moderate and severe periodontitis, bone loss, percentage of deep pockets, greater attachment loss in RA patients compared to systemic health patients [6–11]. A recent systematic review evaluated the association between RA and periodontitis including 17 papers with a total of 153,492 patients. The authors observed increased risk of periodontitis in the presence of RA compared to healthy controls (relative risk: 1.13; 95% CI: 1.04, 1.23) with significantly worst clinical periodontal parameters in those with RA [12]. These findings are also confirmed in several animal studies, which show more bone loss and higher levels of inflammatory cytokines in the presence of RA [13–16].

As previously discussed [13], T lymphocytes, macrophages and polymorphonuclear infiltration occur in RA and in periodontitis causing progressive tissue destruction [3, 4, 17]. The maintenance of the inflammatory process is mediated by cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-12, IL-17, IL-18, IL-23 and IFN-γ) in RA and in periodontitis [3, 17–19]. The bidirectional relationship between both diseases has been investigated and studies have showed increase in gingival inflammatory status in the presence of RA [9–11], as well as the increasing of RA occurrence and severity in a periodontitis condition [20]. Considering this, immunomodulation has been a therapeutic approach evaluated [21] for both diseases, especially focusing on natural products [22–28].

Resveratrol (3, 4',5-trihydroxystilbene), a pleiotropic molecule, is a polyphenol not flavonoid, antifungal plant-derived substance that also is present in food like grapes, cranberries and peanuts [29]. Resveratrol has attracted great attention due to several biological properties as improvement of metabolic control of diabetes [30], anti-cancer activity [31], antioxidant enzyme activities [30, 32], protection against neural degeneration [33], and prevention of cardiovascular diseases [34]. Additionally, resveratrol may positively interfere with osteoblastogenesis, contributing to new bone formation [35]. Considering its effect on periodontitis progression, animal studies have showed reduced alveolar bone loss and imuno-modulatory effect [22, 36]. Besides, a protective role of resveratrol on collagen-induced arthritis in mice related to its inhibitory effect on Th17 cell expansion and IL-17 production was observed. Studies in animals [37–39] and in humans [40–42] demonstrated an effective property of resveratrol in suppressing inflammatory activities. However, to the author’s knowledge, there is no study investigating the effect of resveratrol on the progression of both RA and periodontitis associated.

In face of the above evidence, this study investigated the effect of continuous use of resveratrol systemically administered on the progression of experimental periodontitis and arthritis, on the local and serum cytokine levels and on the clinical and articular feature of RA condition.

**Material and methods**

**Animals**

The animals were composed of 34 adults male Wistar rats, weighing between 200 to 300g (Butantan Institute in São Paulo, Brazil) at the beginning of the study. There was a 15 days...
period of acclimatization before use and the animals were kept in temperature-controlled cages, with access to food and water ad libitum. The experimental procedure was approved by the Paulista University Institutional Animal Care and Use Committee (205/13 CEP/ICS/UNIP).

**Experimental design**

**Treatment groups.** The experimental design can be observed in Fig 1. The animals were assigned to one of the three groups: 1—experimental arthritis + experimental periodontitis + placebo (RA+EP+PL) (N = 12); 2—experimental arthritis + experimental periodontitis + ibuprofen (RA+EP+IB) (N = 11); 3—experimental arthritis + experimental periodontitis + resveratrol (RA+EP+RSV) (N = 11). Treatments consisted in daily administration of a placebo solution, 30 mg/kg of ibuprofen [43, 44] and 10 mg/kg of resveratrol [13, 22, 36]. A stock solution of resveratrol (R5010-500MG; Sigma-Aldrich, São Paulo, São Paulo, Brazil) (molecular weight = 228.2) was prepared in 100 mL of Tween-80 (P4780; Sigma-Aldrich, São Paulo, São Paulo, Brazil) and further dilutions of both were made in water to obtain the concentrations required for this investigation. A stock solution of ibuprofen (Brainfarma Indústria Química e Farmacêutica S.A, Anápolis, Goiás, Brasil) was prepared in 1000 mL of water. The placebo solution was composed of the same quantities of Tween-80 and water, as used in the preparation of resveratrol. The therapies were administered via gavage for 30 days–from day 0 to day 30. The animals were evaluated daily throughout the experiment to check for possible clinical or toxicological symptoms. This analysis was performed by weighting the animals 3 times/week, checking daily the food and water consumption and examining clinically any sign of illness different from those caused by AR.

**Rat arthritis model.** As described in detail previously [13], RA was induced by two immunizations of a type-II collagen (CII) (CII; C9879-1G - Sigma-Aldrich, São Paulo, São Paulo, Brazil) (molecular weight = 228.2) was prepared in 100 mL of Tween-80 (P4780; Sigma-Aldrich, São Paulo, São Paulo, Brazil) and further dilutions of both were made in water to obtain the concentrations required for this investigation. A stock solution of ibuprofen (Brainfarma Indústria Química e Farmacêutica S.A, Anápolis, Goiás, Brasil) was prepared in 1000 mL of water. The placebo solution was composed of the same quantities of Tween-80 and water, as used in the preparation of resveratrol. The therapies were administered via gavage for 30 days–from day 0 to day 30. The animals were evaluated daily throughout the experiment to check for possible clinical or toxicological symptoms. This analysis was performed by weighting the animals 3 times/week, checking daily the food and water consumption and examining clinically any sign of illness different from those caused by AR.

![Fig 1. Means ± SD of paw swelling (volume—ml) measured by plethysmometer.](https://doi.org/10.1371/journal.pone.0204414.g001)
Paulo, Brazil) emulsion in Incomplete Freund’s Adjuvant (IFA—F5506–10 mL; Sigma-Aldrich, São Paulo, São Paulo, Brazil) and a third immunization with Complete Freund’s adjuvant (CFA—F5881–10 mL; Sigma-Aldrich, São Paulo, São Paulo, Brazil). The first injection was composed by a total of 300 μg of CII in IFA in several points of the tail base and the second dose (booster dose) consisted of 100 μg of CII in IFA, subcutaneously. The third immunization included two injections of CFA (1mg/ml) made in the paw subcutaneously (0.1 ml) and in the knee joint via intra-articular (0.1 mL).

**Rat periodontitis model.** Experimental periodontitis was induced in one of the mandibular first molars of each animal through the placement of cotton ligature (Corrente Algodão 10, Coats Corrente, São Paulo, São Paulo, Brazil) knotted subgingivally at the cementoenamel junction, as previously described [13,22]. The presence of the ligatures submarginally permitted the biofilm accumulation over 30 days. The contralateral teeth did not receive ligatures and were used as a control. The animals were anesthetized by the intramuscular administration of ketamine hydrochloride (0.5 mL/kg) and xylazine hydrochloride (10 mg/kg).

**Euthanasia and specimens collecting.** The euthanasia occurred 51 days after the beginning of the study using CO₂ inhalation and the mandibles were excised for morphometric analysis. The buccal gingival tissue from the area surrounding the lower first molar subjected to experimental periodontitis was also collected for immune-inflammatory analysis using Luminex/MAGpix assay.

**Measurement of alveolar bone loss.** The specimens were prepared after gingival dissection, as described in detail previously [13, 22]. Briefly, the mandibles were de-fleshed after immersion in 8% sodium hypochlorite for 4 h and then the specimens were washed in running water and dried with compressed air. An 1% aqueous methylene blue solution (Sigma-Aldrich, St. Louis, MO) was applied to the specimens to distinguish the cementum enamel junction (CEJ) and after this they were washed in running water. Photographs of the buccal aspects were taken, and representative linear alveolar bone loss was assessed on the buccal surface of the lower first molars by measuring the distance of the CEJ from the alveolar bone crest at three equally distant sites. To validate measurement conversions, all specimens were photographed alongside a millimeter ruler [13, 22, 23, 36]. A single examiner (PRP), who was blinded to the experimental group identities, carried out morphometric measurements. The measurements were performed after intraexaminer calibration by evaluating 10 images twice within 24 hours, obtaining an intraclass correlation of 91%.

**Immunoenzymatic assay.** This procedure was carried out as described previously by the authors of the present study [13]. The collected tissues were placed into sterile tubes containing 400μl phosphatebuffered saline (PBS) with 0.05% Tween-20 and the samples were stored at -20°C until the analysis. Next, the tissue was weighed, cut into small pieces (1 mm³ to 2 mm³), and solubilized in PBS (100 mg tissue/ml). The levels of IL-4, IL-1β, IL-6, IL-17 and TNF-α were determined by Luminex/MAGpix assay using commercially available kits (RCYTO-MAG-80K; Millipore, Billerica, MA, USA) and following the manufacturers’ instructions. The standard curve range used for IL-1β measurement was 2.4–10,000 pg/ml; for IL-4 measurement, 4.9–20,000 pg/ml; for IL-6 7.3–300,000 pg/ml, for TNF-α 2.4 to 10,000 pg/ml; and for IL-17 7.3 to 30,000 pg/ml.

**Rheumatoid Arthritis factor serum levels and anti-citrullinated protein antibody gingival levels.** RF serum levels and ACCPA gingival levels were performed as described before [13]. Blood was collected from eye arteria at day 0 (T1) and day 30 (Euthanasia–T2) and the serum samples were stored at −70°C. For some animals, it was not possible to collect the necessary blood volume for the analysis. The gingival tissue was prepared as described above for multiplex immunoenzymatically assay and some samples were lost during the assay conducton. The level of RF and anti-citrullinated protein antibody in serum aliquots and gingival
tissue were measured by using Rat Elisa Kits (MBS720877—monoclonal anti-RF antibody and an RF-HRP conjugate; Mybiosource, San Diego, California, USA; E-EL-R1431—monoclonal antibody specific to and Avidin-Horseradish Peroxidase (HRP) conjugate -Elabscience, Beijing, China, respectively).

**Paw swelling analysis.** For the assessment of paw swelling, the measurement was performed weekly using a volume displacement plethysmometer (Ugo Basile, Varese, Italia) [13].

**Histological procedure.** The whole knee joints, including synovium, adjacent tissues and bones were collected and preserved in 10% formalin solution. The joints were transversely sectioned (4–5 mm thick sections) and stained with standard Hematoxylin and Eosin (H&E). Sections were viewed by the aid of a light microscope attached with a digital camera. It was performed a descriptive evaluation concerning the joint cartilage (intact, smooth or irregular articular surface), the quantity of congested vessels and the width of subchondral cortical.

**Statistical analysis**

Kruskal-Wallis/Dunn (intergroup) and Paired t test were performed (intragroup) for alveolar bone loss and cytokine levels. RF serum levels and gingival ACCPA levels were analyzed by Wilcoxon (intragroup) and Kruskal-Wallis/ Dunn tests (intergroup). In addition, a two-way ANOVA/Tukey test was used for plethysmometer values. The significance level for all analyses was 5% (Statistical Analysis System—SAS—9.3, Cary, NC, USA).

**Result**

**Clinical and histological analysis**

The only sign of systemic illness observed during the experimental period consisted of RA and loss of weight or deaths were not observed. In accordance with our previous study using this RA model [13], 21 days after immunization, joint swelling was observed first in the hind paws, and then joint swelling extended to the forelegs and tail. The peak of the disease occurred on day 28, with multiple and symmetrical joint swelling and redness, and the greater paw volume was noted at the paw that received the third immunization. Deformity and limited mobility were observed in some joints of some animals.

Regarding the plethysmometer analysis, increase in swelling after RA induction was observed confirming the efficacy of the RA model through the significant difference among the values of baseline (-21) and days: -7, 7, 14, 21 and 28 for placebo group; days -7, 7, 21 and 28 for ibuprofen group; days -7, 14, 21 and 28 for RSV group (p<0.05). At day 21, ibuprofen and RSV groups showed lower levels of paw edema than the placebo group (p<0.05) and at day 28 only RSV group showed a reduction in paw swelling (p<0.05) (Fig 1). However, RA symptoms (joints swelling and deformities) were observed throughout the experimental period in all groups, being the RSV group with less pronounced symptoms. Additionally, signs of gingival inflammation (redness, swelling, bleeding) were confirmed clinically during the euthanasia around the ligated teeth of all groups, with no signs of inflammation at the non-ligated sites.

Histologic evaluation of the joint in placebo group showed irregular articular surface, wider articular cartilage and chondrocytes showing pyknotic nuclei. It was also observed congested vessels. Ibuprofen group showed a smooth articular surface with thickened articular cartilage, but not as thick as in the placebo group. Besides, the chondrocytes show hyper cellularity. RSV group presented smooth articular surface. The articular cartilage shows hyper cellularity and aggregation of chondrocytes. Fig 2 illustrates the histological aspect of the joints.
Morphometrical results

Intergroup comparison of the morphometric outcomes revealed higher bone loss values in RA +EP+PL (p < 0.05) when compared to RA+EP+IB and RA+EP+RSV. There was no difference in bone loss values between RA+EP+IB and RA+EP+RSV groups (p>0.05). There was no difference between groups in unligated teeth (p>0.05). The morphometric findings are shown in Table 1 and Fig 3 illustrates the morphometric findings.

Gingival tissue interleukin and ACCPA levels

Analysis of inflammatory markers in gingival tissues collected at the end of the experimental period (T2) showed higher levels of IL-4 in the RA+EP+RSV group than in the control and ibuprofen groups (p<0.05). Placebo group had lower concentration of IL-4 in the ligated sites than in the unligated sites (p<0.05). Intergroup analyzes of IL-1β, IL-6, IL-17 and TNF-α revealed no differences among the groups (p>0.05) (Table 2). Besides, the RA+EP+PL group had the highest values of ACCPA (p<0.05), and ibuprofen promoted a greater reduction than RSV in these levels (p<0.05). Values are demonstrated at Table 3.

RF serum levels

The levels of RF in T1, prior to EP, presented no difference among the groups (p<0.05). The levels of RF increased from T1 to T2 (time of euthanasia) in RA+EP+PL and in RA+EP+IB (p<0.05), but not in RA+EP+RSV (p>0.05). Additionally, at T2 the RSV group presented lower concentration of RF than placebo and ibuprofen groups (p<0.05). (Table 4).

Discussion

The link between rheumatoid arthritis and periodontitis and the bidirectional pathway of their development has been reported by important clinical studies [6–11, 45–47] and systematic reviews [12, 48–50]. One disease seems to alter the imuno-inflammatory response of another, such as the concentration of pro-inflammatory cytokines, RF and ACCPA serum and gingival levels [13]. The effect of resveratrol has been investigated in the treatment of both RA [51–52] and periodontitis [22, 36], but not when the diseases are associated. This study evaluated the influence of systemic treatment with resveratrol on the progression of both diseases. Resveratrol and ibuprofen promoted lower alveolar bone loss and lower gingival levels of ACCPA than placebo. Only resveratrol was capable to modulate the local levels of IL-4 and the serum levels of rheumatoid factor. Additionally, RSV seems to reduce the clinical feature of RA, with reduced paw swelling throughout the time, and histologically, it seems to promote articular protection.

IL-4 is an anti-inflammatory cytokine and it is well known that its concentration is reduced in periodontal compromised patients [53–55]. This cytokine is an inhibitor of production of pro-inflammatory cytokines TNF-α, IL-1α, IL-1β, IL-6 and IL-8 [56, 57]. IL-4 is also a B cell stimulatory factor and promotes immunoglobulin (Ig) class switching to IgE [58]. Thus, low level of IL-4 results in higher periodontal destruction and higher levels act as protective role in periodontitis. Higher levels of IL-4 promotes the regulation of immune function and reduced macrophage survival in the inflammatory lesion. In the present study, it was observed lower alveolar bone loss when ibuprofen and resveratrol were administered. Additionally, the results showed modulatory effect of RSV in IL-4 levels, which can explain the lower bone loss in the RSV group, as showed in a previous study of our research group [36] where the systemic treatment of resveratrol increased the gingival levels of IL-4 in a rat ligature-induced periodontitis model. Moreover, IL-4 levels were higher at RSV-treated group on the periodontitis-induced
Fig 2. Representative photomicrographs of articular cartilages of the different groups.

https://doi.org/10.1371/journal.pone.0204414.g002
gingival tissue when compared to the non-periodontitis-induced tissue, confirming the protective effect of this marker. Ibuprofen did not modulate IL-4 levels, nor the other cytokine levels in our study, suggesting that the pathway by ibuprofen reduces periodontal breakdown may be through another mechanism not investigated in the study. A periodontitis beagle model in which ibuprofen was systemic applied resulted in reduced levels of PGE$_2$ and thromboxane in gingival fluid and lowered alveolar bone loss when compared to the control animals [59]. Besides, although the association of ibuprofen and other non-steroidal anti-inflammatory drugs to periodontal non-surgical therapy have been demonstrated as a positive approach [60], the use of this type of drug can result in several adverse effects, as gastrointestinal

Table 1. Mean ± SD of alveolar bone loss (millimeters) for ligated and unligated teeth.

|                  | MEAN LIGATED±SD | MEAN UNLIGATED±SD | p-value (intragroup) |
|------------------|-----------------|-------------------|----------------------|
| RA+EP+PL (N = 12) | 1.61±0.07 †     | 1.24±0.09         | 0.0001               |
| RA+EP+IB (N = 11) | 1.52±0.06 *      | 1.27±0.07         | 0.0001               |
| RA+EP+RSV (N = 11)| 1.48±0.09 *     | 1.21±0.12         | 0.0001               |
| p-value (inter-group) | 0.0014         | 0.3230            |                      |

†Significant difference for RA+EP+IB and RA+EP+RSV when compared to RA+EP+PL by (ANOVA/Tukey test; p<0.05).

No significant intergroup differences were observed from ANOVA, p > 0.05 to unligated sites.

https://doi.org/10.1371/journal.pone.0204414.t001

Fig 3. Representative photographs illustrating the morphometric findings of the groups.

https://doi.org/10.1371/journal.pone.0204414.g003
problems, bleeding (as a result of decreased platelet aggregation), renal and hepatic impairment. In addition, since there is cessation of ingestion of these drugs, there may be a return or rebound effect on the rate of bone loss [61].

The modulation of IL-4 levels by resveratrol is an important finding regarding the progression of rheumatoid arthritis. It has been shown that IL-4 reduces joint inflammation and bone destruction [62–64]. Besides, IL-4 secreted by dendritic cells suppressed IL-17 production by T cells in the early phase of CIA, reducing the incidence and severity of the disease [62, 65]. In addition, IL-4 was related to the inhibition of IL-1β production and to the increasing production of IL-1 receptor antagonist in rheumatoid synovial explants. Taken together, these results may be related to the reduction of inflammatory signs of RA in the present study represented by the reduction in paw edema at the 28th and to the articular improvement seen in the histological findings in the RSV group.

Our results show no difference regarding the levels of the other cytokines analyzed (IL-1β, IL-6, IL-17, TNF-α) among the groups and this may be related to the coexistence of both periodontitis and rheumatoid arthritis, which may exacerbate the immune-inflammatory response and the administered substances could not overcome this effect. Our research group showed an upregulation of IL-17 with the association of both diseases in rats [13] and it is well known that Th17 plays an important role in the pathogenesis of collagen-induced arthritis, inducing the production of IL-1, TNF-α, IL-6, IL-8, GM-CSF and PGE2 [63, 66–68], as well as in the periodontitis development leading to osteoclastogenesis [69–71]. In the present study, no significant difference in the levels of IL-17 was showed even with the administered treatments and it may be hypothesized that resveratrol and ibuprofen were not able to modulate the level of this marker due to the elevated levels of IL-17 released by the association of both pathologies.

Table 2. Means ± SD of IL-4, IL-1β, IL-6, IL-17 and TNF-α concentrations (picograms per milliliter) measured by multiplex assay.

| Group                  | IL-4     | IL-1β    | IL-6     | IL-17    | TNF-α    |
|------------------------|----------|----------|----------|----------|----------|
|                         | Ligated  | Unligated| Ligated  | Unligated| Ligated  | Unligated| Ligated  | Unligated| Ligated  | Unligated|
| RA+EP+PL (N = 11)       | 0.03±0.03| 0.07±0.05| 0.66±0.55| 0.49±0.42| 0.30±0.46| 0.17±0.14| 0.10±0.14| 0.08±0.04| 0.03±0.03| 0.04±0.02|
| RA+EP+IB (N = 11)       | 0.08±0.08| 0.10±0.12| 1.52±0.96| 0.68±0.61| 0.12±0.10| 0.41±0.38| 0.21±0.24| 0.14±0.12| 0.05±0.06| 0.04±0.04|
| RA+EP+RSV (N = 9)       | 0.10±0.10†| 0.10±0.08| 0.95±0.69*| 0.41±0.34| 0.27±0.37| 0.20±0.23| 0.13±0.02| 0.09±0.04| 0.04±0.02| 0.04±0.01|
| p-value                | 0.257    | 0.661    | 0.064    | 0.528    | 0.856    | 0.291    | 0.327    | 0.736    | 0.296    | 0.501    |

† Significant difference for intragroup comparison by Paired T test—p < 0.05.
† Significance difference for RA+EP+RSV when compared to RA+EP+PL by Kruskal-Wallis/Dunn test—p < 0.05.
No significant inter-group differences were observed from the Kruskal-Wallis test, p > 0.05 to unligated sites.

Table 3. Means ± SD of anti-citrullinated protein antibody (ACCPA) gingival levels (U/ml) measured by ELISA assay.

| GINGIVAL TISSUE | Group                  |
|-----------------|------------------------|
|                 | RA+EP+PL (N = 5)       |
|                 | 50.96±13.60†           |
|                 | RA+EP+IB (N = 5)       |
|                 | 0.02±0.01              |
|                 | RA+EP+RSV (N = 5)      |
|                 | 14.28±3.32‡            |
| p-value         | < 0.0001               |

† Significant difference for RA+EP+IB and RA+EP+RSV when compared to RA+EP+PL (ANOVA/Tukey test; p<0.05).
‡ Significant difference for RA+EP+IB when compared to RA+EP+RSV (ANOVA/Tukey test; p<0.05).
In line, resveratrol modulated the serum levels of Rheumatoid factor and the local levels of anti-citrullinated protein antibody. Both markers are related to increased disease activity and severity [72–74]. Interestingly, studies have showed that RF influences the size of bone erosions on an ACCPA background in a dose dependent manner [75]. Additionally, systemic bone mineral density in patients with early RA is reduced in relation with ACCPA positivity and high RF levels. An animal study suggested that the elevated local levels of ACCPA observed when RA and EP were associated would contribute to periodontal destruction [13]. In accordance with our results, Whaba et al. [76] observed a significant reduction in RF serum levels of arthritic rats improving AR progression. These findings can help to explain the lower bone loss, as well as, the reduction in paw edema and the articular damage in the RSV group. Although ibuprofen has reduced the local levels of ACCPA to a lower level than the reduction promoted by RSV, RF levels were not modulated by it. Thus, the control of the paw edema in ibuprofen group did not extended to the end of the experiment. At the same way, the articular improvement observed histologically was not compared to that seen in RSV group.

Both IB and RSV reduced the levels of ACCPA in the present study. This finding can be related to the lower periodontal destruction in the related groups once the citrullination process alters the complement system activity, inactivates epidermal growth factor and induces prostaglandin E₂ (PGE₂) production [77–80], leading to a possible higher periodontal destruction. Additionally, it was also shown a directly association between alveolar bone loss and ACCPA levels [13]. It can be hypothesized that both substances could act reducing the citrullination process. With the above evidence, it can be suggested that both substances promoted protective role in periodontal tissues regarding ACCPA local influence.

The results of the present study can suggest a potential of host modulation by resveratrol when both conditions coexist. The reduction in IL-4 gingival levels may reduce the periodontal breakdown as well as the progression of rheumatoid arthritis. Besides, resveratrol modulated the serum levels of RF and the local levels of ACCPA, which can result in reduction of activity and severity of RA. Additionally, lower ACCPA gingival levels can also reduce the periodontal destruction. Interestingly, a recent clinical trial administered 1g/day of resveratrol with the conventional treatment of RA for 3 months observing reduction in clinical markers, disease activity and inflammatory markers. The author think that different doses should be used to test the effect of lower doses both in RA alone and in conditions of association of both diseases [81]. The observed modulatory effects of resveratrol in the presence of the diseases can suggest the use of a clinical approach for patients who present both conditions and clinical studies evaluating different doses should be conducted to confirm these findings.

Considering the limits of this study, it can be concluded that resveratrol can reduce periodontal destruction and ACCP local levels in the presence of rheumatoid arthritis. However only resveratrol showed modulatory effect on the levels of IL-4 and rheumatoid factor in

### Table 4. Means ± SD of rheumatoid factor (RF) serum levels (U/ml) measured by ELISA assay.

| Condition                      | T1       | T2       | p-value (intragroup) |
|-------------------------------|----------|----------|-----------------------|
| RA+EP+PL (N = 8)              | 71.88±4.48 | 78.06±3.07 | 0.26                  |
| RA+EP+IB (N = 8)              | 67.97±3.30 | 76.49±3.31 | < 0.0001              |
| RA+EP+RSV (N = 8)             | 68.25±7.81 | 72.66±4.23 | 0.166                 |

p-value (inter-group) 0.187 < 0.05

*Significant difference for intragroup comparison (Paired T test—p < 0.05).
†Significant difference for RA+EP+RSV when compared to RA+EP+PL in T2 (ANOVA/Tukey test; p<0.05).

https://doi.org/10.1371/journal.pone.0204414.t004
arthritic rats and reduce the inflammatory signs of arthritis and articular damage throughout the time.

**Supporting information**

S1 File. Supporting information. (XLSX)

**Acknowledgments**

This study was partially supported by grant from the National Counsel of Technological and Scientific Development—(CNPq—Brasília, Distrito Federal, Brazil) (442275/2014-5; Renato Corrêa Viana Casarin). This work was also supported by Research Productivity Fellowship to M.H.N, and M.Z.C. from CNPq.

**Author Contributions**

**Conceptualization:** Marcio Z. Casati, Renato Corrêa Viana Casarin.

**Data curation:** Mônica G. Corrêa, Fernanda Vieira Ribeiro, Renato Corrêa Viana Casarin.

**Formal analysis:** Renato Corrêa Viana Casarin.

**Funding acquisition:** Renato Corrêa Viana Casarin.

**Investigation:** Mônica G. Corrêa, Paula Rodrigues Pires, Suzana Peres Pimentel, Fabiano Ribeiro Cirano.

**Methodology:** Mônica G. Corrêa, Fernanda Vieira Ribeiro, Marcelo Henrique Napimoga.

**Project administration:** Renato Corrêa Viana Casarin.

**Supervision:** Marcio Z. Casati, Renato Corrêa Viana Casarin.

**Visualization:** Fernanda Vieira Ribeiro, Suzana Peres Pimentel, Fabiano Ribeiro Cirano, Marcio Z. Casati.

**Writing – original draft:** Mônica G. Corrêa.

**Writing – review & editing:** Mônica G. Corrêa, Marcelo Henrique Napimoga, Marcio Z. Casati, Renato Corrêa Viana Casarin.

**References**

1. Tobon GJ, Youinou P, Saraut A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010; 35:10e4.

2. Petersen PE, Ogawa H. The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontol 2000. 2012; 60:15–39. https://doi.org/10.1111/j.1600-051X.2011.00425.x PMID: 22909104

3. Kinane DF, Preshaw PM, Loos BG. Working Group 2 of Seventh European Workshop on Periodontology. Host-response: understanding the cellular and molecular mechanisms of host-microbial interactions-consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011; 38: 44–48. https://doi.org/10.1111/j.1600-051X.2010.01682.x PMID: 21323703

4. Hitchon CA, El-Gabalawy HS. Infection and rheumatoid arthritis: still an open question. Curr Opin Rheumatol 2011; 23:352–7. https://doi.org/10.1097/BOR.0b013e3283477b7b PMID: 21532483

5. Detert J, Pischon N, Burmester GR, Buttgerfeit F. The association between rheumatoid arthritis and periodontal disease. Arthritis Res Ther 2010; 12:218. https://doi.org/10.1186/ar3106 PMID: 21062513

6. Choi IA, Kim JH, Kim YM, Lee JY, Kim KH, Lee EY, et al. Periodontitis is associated with rheumatoid arthritis: a study with longstanding rheumatoid arthritis patients in Korea. Korean J Intern Med 2016; 31 (5):977–86. https://doi.org/10.3904/kjim.2015.202 PMID: 27017391
7. Silvestre-Rangel J, Bagán L, Silvestre FJ, Bagán JV. Oral manifestations of rheumatoid arthritis. A cross-sectional study of 73 patients. Clin Oral Investig 2016; 20(9):2575–2580. https://doi.org/10.1007/s00784-016-1745-z PMID: 26888220

8. Santegoets KC, Wenink MH, Braga FA, Cossu M, Lamers-Karnebeek FB, van Riel PL, et al. Impaired Porphyromonas gingivalis-Induced Tumor Necrosis Factor Production by Dendritic Cells Typifies Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68(4):795–804. https://doi.org/10.1002/-art.39514 PMID: 26606260

9. de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol 2008; 35(1):70e6.

10. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 2000; 27(4):267–272. PMID: 10783841

11. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontal disease. J Periodontol 2001; 72(6):779–787. https://doi.org/10.1902/jop.2001.72.6.779 PMID: 11453241

12. Fuggle NR, Smith TO, Kaul A, Sofat N. Hand to Mouth: A Systematic Review and Meta-Analysis of the Association between Rheumatoid Arthritis and Periodontitis. Front Immunol 2016; 2; 7:80.

13. Corrêa MG, Sacchetti SB, Ribeiro FV, Pimentel SP, Casarin RC, Cirano FR, et al. Periodontitis increases rheumatic factor serum levels and citrullinated proteins in gingival tissues and alter cytokine balance in arthritic rats. PLoS One 2017; 12(3):e0174442 https://doi.org/10.1371/journal.pone.0174442 PMID: 28358812

14. Queiroz-Junior CM, Madeira MF, Coelho FM. Experimental arthritis exacerbates Aggregatibacter actinomycetemcomitans-induced periodontitis in mice. J Clin Periodontol 2012; 39 (7):608–16. https://doi.org/10.1111/j.1600-051X.2012.01886.x PMID: 22582749

15. Trombone AP, Claudino M, Colavite P, de Assis GF, Avila-Campos MJ, Silva JS, et al. Periodontitis and arthritis interaction in mice involves a shared hyper-inflammatory genotype and functional immunological differences. Genes Immun 2010; 11(6):479–89. https://doi.org/10.1038/gene.2010.13 PMID: 20428191

16. Ramamurthy NS, Greenwald RA, Celiker MY, Shi EY. Experimental arthritis in rats induces biomarkers of periodontitis which are ameliorated by gene therapy with tissue inhibitor of matrix metalloproteinases. J Periodontol 2005; 76(2):229–33. https://doi.org/10.1902/jop.2005.76.2.229 PMID: 15974846

17. Filippini L, Vercelino R, Marroni NP, Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 2008; 152(3):415–22. https://doi.org/10.1111/j.1365-2249.2008.03634.x PMID: 18422737

18. Garlet GP. Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. J Dent Res 2010; 89:1349–1363 https://doi.org/10.1177/0022034510376402 PMID: 20739705

19. Moynagh PN. The NF-kappaB pathway. J Cell Sci 2005; 15(Pt20):4589–92.

20. Chou YY, Lai KL, Chen DY, Lin CH, Chen HH. Rheumatoid Arthritis Risk Associated with Periodontal Disease: A Nationwide, Population-Based Cohort Study. PLoS One. 2015 Oct 1; 10(10):e0139693. https://doi.org/10.1371/journal.pone.0139693 PMID: 26426533

21. Carregaro V, Napimoga MH, Peres RS, Benevides L, Sacramento LA, Pinto LG, et al. Therapeutic Treatment of Articular Mice with 15-Deoxy Δ(12,14)-Prostaglandin J(2) (15d-PGJ(2)) Ameliorates Disease through the Suppression of Th(17) Cells and the Induction of CD4(+)/CD25(-)/FOXP3(+)/CD122 Cells. Mediators Inflamm 2016; 962427.

22. Casati MZ, Algayer C, Cardoso da Cruz, Ribeiro FV, Casarin RC, Pimentel SP, et al. Resveratrol decreases periodontal breakdown and modulates local levels of cytokines during periodontitis in rats. J Periodontol 2013; 84(10):58–64.

23. Barrella GE, Saffredi IB, Ribeiro FV, Cirano FR, Pimentel SP. Evaluation of the effect of an organic extract obtained from Ipomoea alba L. on experimental periodontitis in rats. Braz Oral Res 2012; 26:158–164. PMID: 22473352

24. Ribeiro FV, Barrella GE, Casarin RCV, Cirano FR, Foglio MA, Pimentel SP. Effect of crude extract and essential oil of Cordia verbena in experimental periodontitis in rats. Braz J Oral Sci 2012; 11:42–46.

25. Pádua TA, de Abreu BS, Costa TE, Nakamura MJ, Valente LM, Henriques Md, et al. Anti-inflammatory effects of methyl ursolate obtained from a chemically derived crude extract of apple peels: potential use in rheumatoid arthritis. Arch Pharm Res 2014; 37(11):1487–95. https://doi.org/10.1007/s12272-014-0345-1 PMID: 24733672

26. Zhang CF, Zhang SL, He X, Yang XL, Wu HT, Lin BQ, et al. Antioxidant effects of Genkwa flos flavonoids on Freund's adjuvant-induced rheumatoid arthritis in rats. J Ethnopharmacol 2014; 153(3):793–800. https://doi.org/10.1016/j.jep.2014.03.046 PMID: 24685587
36. Tseng PC, Hou SM, Chen RJ, Peng HW, Hsieh CF, Kuo ML, et al. Resveratrol promotes osteogenes

28. Xuzhu G, Komai-Koma M, Leung BP, Leung BP, Howe HS, McSharry C, et al. Resveratrol modulates
murine collageninduced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 2012; 71:129–135.
https://doi.org/10.1136/ard.2011.149831 PMID: 21953348

29. Baur JA, Sinclair DA. The therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov
2006; 5(6):493–506. https://doi.org/10.1038/nrd2060 PMID: 16732220

30. Soufi FG, Sheeravallou R, Vardiani M, Khalili M, Alipour MR. Chronic resveratrol administration has benefi
cial effects in experimental model of type 2 diabetic rats. Endocr Regul 2012; 46:83–90. PMID:
22540856

31. Whitlock NC, Baek SJ. The anticancer effects of resveratrol: modulation of transcription factors. Nutr
Cancer 2012; 64:493–502. https://doi.org/10.1080/01635581.2012.667862 PMID: 22482424

32. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthes uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol
2011; 30:258–264.

33. Li Z, Pang L, Fang F, Zhang G, Zhang J, Xie M, et al. Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via up-regulation of hippocampal Bcl-2. Brain Res 2012; 23:116–124.

34. Breen DM, Dolinsky VW, Zhang H, Ghanim H, Guo J, Mroziewicz M, et al. Resveratrol inhibit s neointi-
mal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis 2012; 222:375–381. https://doi.org/10.1016/j.atherosclerosis.2012.03.021 PMID:
22552115

35. Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, de Avila J, Munevar JC, et al. Periodontal Disea-se in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-

37. Baur JA, Sinclair DA. The therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov
2006; 5(6):493–506. https://doi.org/10.1038/nrd2060 PMID: 16732220

38. Rotondo S, Rajtar G, Manarin i S, Celardo A, Rotillo D, de Gaetano G, et al. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmac
1998; 123(8):1691–9. https://doi.org/10.1038/sj.bjp.0701784 PMID: 9605577

39. Corrêa MG, Pires PR, Ribeiro FV, Pimentel SZ, Casarin RC, Cirano FR, et al. Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats. J Periodontal
Res 2017; 52(2):201–209. https://doi.org/10.1111/jre.12382 PMID: 27135637

40. Tomé-Carneiro J, Larrosa M, Yañez-Gascón MJ, Dávalos A, Garcia Almagro JF, Ruiz Ros JA, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokine expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmaco Res 2013; 72:69–82. https://doi.org/10. 1016/j.phrs.2013.03.011 PMID: 23557933

41. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Oral resveratrol and calcium fructo-
borate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013; 29(1):178–83. https://doi.org/10.1016/j.nut.2012.07.006 PMID:
23153742

42. Ghanim H, Sia CL, Murthy BV, Akula A. Cerebro protective potential of resveratrol through anti-oxidant and anti-
inflammatory mechanisms in rats. J Neural Transm 2013; 120(8):1217–23. https://doi.org/10.1007/
s00702-013-0982-4 PMID: 23731441

43. Tomé-Carneiro J, Larrosa M, Yañez-Gascón MJ, Dávalos A, Garcia Almagro JF, Ruiz Ros JA, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokine expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmaco Res 2013; 72:69–82. https://doi.org/10. 1016/j.phrs.2013.03.011 PMID: 23557933

44. Rutten K, Schiene K, Robens A, Leipelt A, Pasqualon T, Read SJ, et al. Burrowing as a non-reflex beha-
vioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation. Eur J Pain
2014; 18(2):204–12. https://doi.org/10.1002/ejpt.1532-2149.2013.00358.x PMID: 23853119

45. Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, De Avila J, Munevar JC, et al. Periodontal Disea-se in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-

46. Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohyd-rate meal. J Clin Endocrinol Metab 2011; 96(5):1409–14. https://doi.org/10.1210/jc.2010-1812 PMID:
21289251

47. Kaur S, Bijjem KR, Sharma PL. Anti-inflammatory and antihyperalgesic effects of the combination of ibuprofen and hemin in adjuvant-induced arthritis in the Wistar rat. Inflammopharmacology 2011; 19 (5):265–72. https://doi.org/10.1007/s10778-011-0090-8 PMID: 21858725

48. Rutten K, Schiene K, Robens A, Leipelt A, Pasqualon T, Read SJ, et al. Burrowing as a non-reflex beha-
vioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation. Eur J Pain
2014; 18(2):204–12. https://doi.org/10.1002/ejpt.1532-2149.2013.00358.x PMID: 23853119

49. Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, De Avila J, Munevar JC, et al. Periodontal Disea-se in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-

50. Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, De Avila J, Munevar JC, et al. Periodontal Disea-se in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-

51. Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, De Avila J, Munevar JC, et al. Periodontal Disea-se in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-

52. Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, De Avila J, Munevar JC, et al. Periodontal Disea-se in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-
Sectional Study. J Periodontol 2016; 87(4):346–56. https://doi.org/10.1902/jop.2015.150455 PMID: 26609697

46. Havemose-Poulsen A, Westergaard J, Stoltze K, Skjødt H, Dannekleid-Samsee B, Loch H, et al. Periodontal and hematological characteristics associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. J Periodontol 77(2): 280–288. https://doi.org/10.1902/jop.2006.050051 PMID: 16460255

47. Ribeiro J, Leao A, Novaes AB. Periodontal infection as a possible severity factor for rheumatoid arthritis. J Clin Periodontol 2005; 32(4): 412–416. https://doi.org/10.1111/j.1600-051X.2005.00689.x PMID: 15811060

48. Calderaro DC, Corrêa JD, Ferreira GA, Barbosa IG, Martins CC, Silva TA, et al. Influence of periodontal treatment on rheumatoid arthritis: a systematic review and meta-analysis. Rev Bras Reumatol 2016; S0482-5004(16)30144-9.

49. Tang Q, Fu H, Qin B, Hu Z, Liu Y, Liang Y, et al. A Possible Link Between Rheumatoid Arthritis and Periodontitis: A Systematic Review and Meta-analysis. Int J Periodontics Restorative Dent 2017; 37(1):79–86. https://doi.org/10.11607/prd.2656 PMID: 27977821

50. Silvestre FJ, Silvestre-Ranjl J, Bagán L, Bagán JV. Effect of nonsurgical periodontal treatment in patients with periodontitis and rheumatoid arthritis: A systematic review. Med Oral Patol Oral Cir Buca 2016; 21(3): e349–54. https://doi.org/10.4317/medoral.20974 PMID: 26946202

51. Riveiro-Naveira RR, Valcárcel-Ares MN, Vaamonde-García C, Loureiro J, Hermida-Carballo L, et al. Resveratrol lowers synovial hyperplasia, inflammatory markers and oxidative damage in an acute anti-immunogen-induced arthritis model. Rheumatology (Oxford) 2016; 55(10):1889–900.

52. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation. 2007 Apr; 30(1–2):1–6. https://doi.org/10.1007/s10753-006-9012-0 PMID: 17115116

53. Kabashima H, Nagata K, Hashiguchi I, Toriya Y, Iijima T, Maki K, et al. Interleukin-1 receptor antagonist and interleukin-4 in gingival crevicular fluid of patients with inflammatory periodontal disease. J Oral Pathol Med 1996; 25:449–53. PMID: 8930824

54. Bastos MF, Lima JA, Vieira PM, Mestnik MJ, Faveri M, Duarte PM. TNF-alpha and IL-4 levels in generalized aggressive periodontitis subjects. Oral Dis 2009; 15: 82–7. https://doi.org/10.1111/j.1601-0825.2008.01491.x PMID: 18992018

55. Giannopoulos C, Kamma JJ, Mombelli A. Effect of inflammation, smoking and stress on gingival crevicular fluid cytokine level. J Clin Periodontol 2003; 30:145–53. PMID: 12622857

56. te Velde AA, Huijbens RJF, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1b, tumor necrosis factor-α and interleukin-6 by human monocytes. Blood 1990; 76:1392–1397. PMID: 2119829

57. Hart PH, Viti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: Suppression of human monocye tumor necrosis factor-α and interleukin-6 by human monocytes. Blood 2119829

58. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77:1859–70. PMID: 2018830

59. Offenbacher S, Williams RC, Jeffcoat MK, Howell TH, Odle BM, Smith MA, et al. Effects of NSAIDs on beagle crevicular cylooxygenase metabolites and periodontal bone loss. J Periodontal Res 1992; 27 (3):207–13. PMID: 1608034

60. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiprotease, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003; 8(1):12–37. https://doi.org/10.1902/annals.2003.8.1.12 PMID: 14971246

61. Preshaw PM. Host response modulation in periodontics. Periodontol 2000. 2008; 48:92–110. https://doi.org/10.1111/j.1600-0757.2008.00252.x PMID: 18715360

62. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001, 107: 1275–1284. https://doi.org/10.1172/JCI11490 PMID: 11375417

63. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105: 1697–1710. https://doi.org/10.1172/JCI7739 PMID: 10862785

64. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999, 1: 81–91. https://doi.org/10.1186/ar14 PMID: 11056663

65. Sarkar S Tesmer LA, Hindnavis V, Endres J, et al. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that...
secrete interleukin-4. Arthritis Rheum 2007, 56: 89–100. https://doi.org/10.1002/art.23311 PMID: 17195211

66. Chabaud J.M. Durand N. Buchs, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42(5): 963–970. https://doi.org/10.1002/art.1032452

67. Jovanovic DV, DiBattista JA, Martel-Pelletier Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1b and TNF-a, by human macrophages. J Immunol 1998; 160(7):3513. PMID: 9531313

68. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T-cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183(6):2593. PMID: 8676080

69. Dutzan N, Gamonal J, Silva A, Sanz M, Vernal R. Overexpression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis. J Clin Periodontol 2009; 36(5):396–403. https://doi.org/10.1111/j.1600-051X.2009.01390.x PMID: 19419438

70. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203(12):2673–2682. https://doi.org/10.1084/jem.20061775 PMID: 17088434

71. Mitani A, Niedbala W, Fujimura T, Mogi M, Miyamae S, Iguchi N, et al. Increased expression of interleukin (IL)-35 and IL-17, but not IL-27, in gingival tissues with chronic periodontitis. J Periodontol 2015; 86(2):301–9. https://doi.org/10.1902/jop.2014.140293 PMID: 25272982

72. Liao F, Li Z, Wang Y, Shi B, Gong Z, Cheng X. Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. Med Hypotheses 2009; 72(6): 732–5. https://doi.org/10.1016/j.mehy.2008.12.040 PMID: 19246161

73. Vander Cruyssen B, Peene I, Cantaert T, Hoffman IE, De Rycke L, Veys EM, et al. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 2005; 4(7):468–74. https://doi.org/10.1016/j.autrev.2005.04.018 PMID: 16137613

74. Humphreys JH, van Nies JA, Chipping J, Marshall T, van der Helm-van Mil AH, Symmons DP, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014; 16(6):483. https://doi.org/10.1186/s13075-014-0483-3 PMID: 25471696

75. Hecht C, Engibrech M, Rech J, Schmidt S, Araujo E, Engellke K, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 2015; 74:2151–6. https://doi.org/10.1136/annrheumdis-2014-205428 PMID: 25115448

76. Wahba MG, Messha BA, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol 2016; 54(9):1705–15. https://doi.org/10.3109/13880209.2015.1125931 PMID: 26704826

77. Shirai H, Mokrab Y, Mizuguchi K. The guanidino-group modifying enzymes: structural basis for their diversity and commonality. Proteins 2006; 64(4):1010–23. https://doi.org/10.1002/prot.20863 PMID: 16779844

78. McGraw WT, Potempa J, Farley D, Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun 1999; 67(7):3248–56. PMID: 10377098

79. Marquis RE, Bender GR, Murray DR, Wong A. Arginine deiminase system and bacterial adaptation to acid environments. Appl Environ Microbiol 1987; 53(1):198–200. PMID: 3105330

80. Casiano-Colón A, Marquis RE. Role of the arginine deiminase system in protecting oral bacteria and an enzymatic basis for acid tolerance. Appl Environ Microbiol 1988; 54(6):1318–24. PMID: 2843090

81. Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH. Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. Clin Rheumatol. 2018 Aug; 37(8):2035–2042. https://doi.org/10.1007/s10067-018-4080-8 PMID: 29611086